You are here

Hepatitis C Patients to Participate in Outcomes Research through App

C Tracker app will allow patients to use technology to participate in studies

C Tracker, an iPhone app developed by Boston Children’s Hospital Computational Health Informatics Program (CHIP), will make it easier for patients with hepatitis C to participate in research studies.  

As reported by PR Newswire, the app will allow people with hepatitis C to volunteer for national or international studies, free of the constraints of geography.

“By and large, the data we have now about hepatitis C treatments come from traditional clinical trials,” explained Kenneth Mandl, MD, MPH, director of CHIP, and principal investigator of the C Tracker project. “With C Tracker, we can listen to the patient voice to learn how people live with hepatitis in the real world.”

“It turns research participation into a patient-driven, democratic endeavor,” adds Mandel.

Patients with chronic hepatitis C–related liver disease can use C Tracker to track their health, medication use, and quality of life over many months or even years. Apple has developed its ResearchKit software so researchers can collect and analyze data from apps using its HealthKit software. 

"Traditional clinical trials are plagued by abysmal accrual rates, slowing progress in discovering cures," Mandl said. "We foresee a future where ResearchKit apps like C Tracker lower the barrier to participation and speed medical progress." C Tracker is free and available for download.

Source: PR Newswire, October 5, 2015

 

Recent Headlines

New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
Drug resistance in HIV patients has nearly tripled since 2001
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI